What are the indications, dosing regimens, monitoring parameters, and adverse effects of guanfacine for hypertension and ADHD?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Guanfacine: Indications, Dosing, Monitoring, and Adverse Effects

Indications

Guanfacine has two distinct FDA-approved indications depending on formulation: immediate-release for hypertension in adults, and extended-release for ADHD in children and adolescents. 1

  • Immediate-release (IR): Treatment of hypertension, typically as monotherapy or in combination with other antihypertensives
  • Extended-release (ER/GXR): Treatment of ADHD in patients aged 6-17 years 2, 3

The 2025 AHA/ACC hypertension guidelines specifically recommend considering nonstimulant medications like guanfacine for ADHD patients when stimulants need to be discontinued or reduced due to blood pressure concerns 4.


Dosing Regimens

For Hypertension (Immediate-Release)

Start with 1 mg daily at bedtime to minimize somnolence; if inadequate response after 3-4 weeks, may increase to 2 mg daily. 1

  • Initial dose: 1 mg at bedtime
  • Maintenance: 1-2 mg daily (most effect seen at 1 mg)
  • Maximum: 3 mg/day (doses above 3 mg significantly increase adverse reactions)
  • Timing: Bedtime dosing preferred to minimize daytime sedation
  • Duration to effect: 3-4 weeks for full assessment 1

For ADHD (Extended-Release)

For children and adolescents, initiate at 1 mg daily and titrate weekly by 1 mg increments based on clinical response and tolerability, targeting weight-adjusted doses of 0.05-0.12 mg/kg/day. 5, 3

  • Children 6-12 years: 1-4 mg/day
  • Adolescents 13-17 years: 1-7 mg/day (up to 9 mg studied in research settings) 5
  • Adults: 2 mg starting dose, maintenance 4-6 mg/day 6
  • Titration: Weekly increases of 1 mg as tolerated
  • Optimal dosing: Weight-adjusted doses >0.08 mg/kg but ≤0.12 mg/kg may provide additional clinical benefits 5

Critical formulation warning: IR and ER formulations are NOT interchangeable. A case report documented severe bradycardia and hypotension requiring PICU admission when a 6-year-old received IR instead of ER formulation 7.


Mechanism and Pharmacokinetics

Guanfacine is a selective α2A-adrenergic agonist that reduces sympathetic outflow from the CNS, decreasing peripheral vascular resistance and heart rate 1.

Key pharmacokinetic parameters:

  • Bioavailability: ~80%
  • Time to peak: 1-4 hours (average 2.6 hours)
  • Half-life: 17 hours (range 10-30 hours; shorter in younger patients at 13-14 hours)
  • Steady state: Achieved within 4 days
  • Excretion: 50% unchanged in urine, 50% as metabolites 1

Monitoring Parameters

Cardiovascular Monitoring (Essential for Both Indications)

Monitor blood pressure and heart rate at baseline, after each dose increase, and regularly during maintenance therapy. 8, 5

  • Blood pressure: Sitting and standing measurements (guanfacine blunts the physiologic BP increase upon standing in a dose-dependent manner) 5
  • Heart rate: Expect average decrease of 5 bpm; monitor for clinically significant bradycardia 1, 8
  • ECG: Consider baseline and follow-up ECG, particularly in patients with cardiac risk factors
    • Recent study showed significant QT interval prolongation (+16.8 ms) but no changes in QTc or novel arrhythmia markers 8
    • Monitor for bradycardia (common adverse effect requiring discontinuation) 8, 7

ADHD-Specific Monitoring

  • ADHD-RS-IV scores: Assess symptom improvement 3
  • CGI-I and PGI-I scales: Global improvement assessment 3, 6
  • Functional impairment: School/learning and family functioning 3

Renal Function

Monitor in patients with renal impairment, as 50% is excreted unchanged renally 1.


Adverse Effects

Most Common Treatment-Emergent Adverse Events

Approximately 80% of patients on guanfacine experience at least one adverse event, compared to 66.5% on placebo, with most being mild to moderate in severity. 2

Top adverse effects by frequency:

  1. Somnolence: 38.6% (most common, dose-dependent) 2, 3
  2. Headache: 20.5% 2
  3. Fatigue: 15.2% 2
  4. Dry mouth 9
  5. Constipation 9
  6. Dizziness/postural dizziness 5, 6
  7. Thirst 6

Cardiovascular Effects

  • Bradycardia: Dose-dependent; can be severe enough to require discontinuation 8, 7
  • Hypotension: Dose-dependent decreases in BP; blunted orthostatic response 5, 7
  • Sinus bradycardia: Common TEAE 5

Serious Considerations

  • Discontinuation rate: In ADHD trials, guanfacine showed dose-dependent discontinuation risk up to 4 mg/day, reaching 9.8% (95% CrI 4.4-20%) 10
  • Formulation errors: Can cause profound hemodynamic instability requiring intensive care 7

Withdrawal Effects

Guanfacine has a lower risk of rebound hypertension compared to clonidine, with delayed onset (2-4 days) and gradual return to baseline pressures. 1

  • Rebound occurs 2-4 days after discontinuation (vs. immediate with clonidine)
  • Blood pressure typically returns to pretreatment levels slowly over 2-4 days
  • Avoid abrupt discontinuation; taper when possible 1

Clinical Pearls and Pitfalls

Critical Warnings

  1. Never substitute IR for ER formulations - this can cause life-threatening bradycardia and hypotension 7
  2. Bedtime dosing for hypertension reduces daytime somnolence 1
  3. Doses above 3 mg/day for hypertension significantly increase adverse reactions without proportional benefit 1
  4. Monitor orthostatic vital signs - the physiologic BP increase upon standing is blunted dose-dependently 5

Efficacy Considerations

  • For hypertension: Most effect seen at 1 mg; 24-hour coverage documented 1
  • For ADHD: Significant improvements in ADHD-RS-IV scores (placebo-adjusted difference -8.9, p<0.001) 3
  • ADHD functional improvements: Learning/school domain and family domain show significant benefits 3
  • Long-term ADHD treatment (50 weeks) shows sustained efficacy with acceptable safety profile 6

Population-Specific Notes

  • White patients: May respond to 1 mg for hypertension 1
  • Black patients: Generally require 2 mg or higher for hypertension 1
  • Younger patients: Shorter half-life (13-14 hours) 1
  • Older patients: Half-life at upper end of range (up to 30 hours) 1
  • Weight >70-90 kg adolescents: Lower clearance at steady state 5

References

Related Questions

What signs and symptoms should be monitored in children (ages 6‑17) receiving guanfacine for attention‑deficit/hyperactivity disorder?
What is the appropriate guanfacine dose for a 100‑lb (≈45‑kg) patient with ADHD?
What is the recommended dosing schedule for guanfacine extended‑release (ER) for ADHD and hypertension, including starting dose, titration increments, and maximum dose?
What is the recommended dosing, titration schedule, and safety precautions for Intuniv (guanfacine extended‑release) in children and adolescents (ages 6–17) with attention‑deficit/hyperactivity disorder?
What is the maximum recommended dose of guanfacine for a 10-year-old male?
What is the interpretation of this urinalysis showing yellow‑straw clear urine, specific gravity 1.015, pH 6.0, leukocyte esterase 500 + (positive), nitrite negative, protein 1 + (positive), ketones 1 + (positive), urobilinogen 2 + (elevated), blood 2 + (positive), red blood cells 21‑50 per high‑power field (HPF), white blood cells too numerous to count per high‑power field (HPF), and bacteria 2 + (positive)?
What is the appropriate evaluation and management for a 35-year-old woman with chronic intermenstrual bleeding, no other symptoms, and not using oral contraceptive pills for the past year?
Should an 82-year-old woman with a 30 pack-year smoking history who continues to smoke half a pack per day undergo low-dose CT lung cancer screening?
If a patient missed one dose of clopidogrel (Plavix) and the P2Y12 platelet function assay is 229, does this indicate a decreased response to clopidogrel?
Should I wait until after discharge to follow up with my primary‑care physician despite having unilateral left‑foot numbness and weakness with reduced dorsiflexion strength?
What are the appropriate dosing parameters and contraindications for using diltiazem as needed to control ventricular rate in atrial fibrillation?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.